Pantoprazol Genilac (Pantoprazole Sodium Sesquihydrate)

Pantoprazole Sodium Sesquihydrate, the active ingredient in Pantoprazol Genilac, is a proton pump inhibitor presented as a tablet for oral use. It reduces stomach acid production and is used to treat acid‑related gastrointestinal conditions in adults and children. GNH USA supplies Pantoprazol Genilac as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Pantoprazol Genilac as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Pantoprazol Genilac is a proton pump inhibitor indicated for conditions affecting gastric acid secretion.

- Gastro‑esophageal reflux disease (GERD): alleviates heartburn and promotes healing of erosive esophagitis. - Peptic ulcer disease (PUD): supports ulcer healing and reduces risk of recurrence. - Zollinger‑Ellison syndrome: controls excessive gastric acid production associated with the condition. - Helicobacter pylori eradication regimens: used as part of combination therapy to improve eradication rates. - NSAID‑induced gastropathy: helps prevent ulcer formation in patients requiring long‑term NSAID therapy.

Pantoprazol Genilac may cause adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhea: usually self‑limiting. - Nausea or vomiting: transient gastrointestinal discomfort. - Abdominal pain or flatulence: occasional bloating. - Constipation: infrequent but reported. - Dry mouth: mild xerostomia.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis with watery diarrhea. - Acute interstitial nephritis: renal inflammation presenting with reduced urine output. - Hypomagnesemia: low serum magnesium levels causing muscle cramps. - Stevens‑Johnson syndrome or toxic epidermal necrolysis: severe skin reactions. - Hepatotoxicity: elevated liver enzymes indicating liver stress. - Bone fractures: increased risk with long‑term use.

Before initiating Pantoprazol Genilac, consider the following precautions:

- Assess renal function: dose adjustment may be required in severe impairment. - Review hepatic status: use with caution in patients with liver disease. - Monitor long‑term users: watch for signs of vitamin B12 deficiency, magnesium loss, and bone density changes. - Evaluate pregnancy status: discuss potential risks and benefits with a healthcare professional. - Consider drug interactions: assess concomitant medications that may affect acid suppression. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Pantoprazole can affect the absorption and metabolism of several medicines. Clinicians should evaluate potential interactions before prescribing.

Major Interactions (Avoid): - Antifungal agents (ketoconazole, itraconazole): reduced absorption leading to therapeutic failure. - HIV protease inhibitors (atazanavir, nelfinavir): decreased plasma concentrations. - Clopidogrel: diminished antiplatelet effect, increasing cardiovascular risk.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR, requiring more frequent monitoring. - Digoxin: elevated serum levels may occur. - Methotrexate: reduced renal clearance can raise toxicity risk. - Oral contraceptives: decreased efficacy, consider alternative contraception.